The information collection is needed
to assure that data from clinical studies meant to demonstrate
safety and efficacy of new products are not compromised by bias
based on financial interests of clinical investigators in the
tested product. This information will be used to identify
potentially biasing financial interests and assess the extent to
which they could affect or have affected the reliability of the
clinical data. Respondents are sponsors who submit marketing
applications to FDA that require clinical data from covered studies
and clinical investigators who submit certain financial
information.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.